Losartan and Progesterone HRT Interaction: What Patients and Clinicians Need to Know

Status note: this article is pending qualified clinical review. It should not be used as a substitute for advice from the prescriber managing your blood pressure or your hormone therapy.

Losartan (Cozaar) is an angiotensin II receptor blocker (ARB) approved for hypertension, certain forms of heart failure, and diabetic nephropathy. Progesterone HRT most often means oral micronized progesterone (brand name Prometrium, typically 100 to 200 mg) or vaginal micronized progesterone, prescribed alongside estrogen for menopausal symptom management or endometrial protection. This article is about that specific pairing, not about synthetic progestins such as medroxyprogesterone acetate, which behave differently in the body and are not covered here.

Direct answer: No FDA label, and no dedicated pharmacokinetic interaction study identified in this review, documents a formal drug-drug interaction between losartan and micronized progesterone. The two drugs do not share a primary metabolic enzyme at standard doses, so a clinically important pharmacokinetic interaction is unlikely. What is plausible, but not established by a controlled interaction trial, is a modest additive effect on blood pressure and on potassium handling, because both drugs influence the renin-angiotensin-aldosterone axis through different routes. This combination is not considered contraindicated, but a clinician should still confirm blood pressure, potassium, and renal function around the time either drug is started or changed.

Why this combination comes up often

Women managing menopause frequently also manage blood pressure, and losartan is one of the more commonly prescribed antihypertensives in the United States. When estrogen-progesterone HRT is started or adjusted in a woman already on losartan, or losartan is started in a woman already on HRT, the prescriber is combining a RAAS-active antihypertensive with a hormone that has its own, separate effects on sodium and potassium handling. That combination is common enough that patients deserve a clear explanation of what is known and what is not, rather than a vague reassurance that "it's fine" or an equally vague warning.

What the FDA labeling actually establishes

Losartan's FDA-approved prescribing information describes hepatic conversion of losartan to its active metabolite, EXP3174, largely through CYP2C9, with a minor contribution from CYP3A4. EXP3174 is substantially more potent than the parent compound at the angiotensin II type 1 receptor and accounts for most of the drug's antihypertensive effect. The label discusses interactions with CYP2C9-active drugs (for example, some azole antifungals) affecting losartan levels, but progesterone is not addressed.

Micronized progesterone's prescribing information describes hepatic and gut-wall metabolism primarily through CYP3A4, producing metabolites including allopregnanolone, which acts on GABA-A receptors and accounts for the sedative effect many patients notice with oral dosing. The label instructs bedtime dosing for this reason. Vaginal or transdermal progesterone produces substantially lower systemic allopregnanolone exposure than oral dosing, which is a labeling-supported reason some clinicians prefer the vaginal route in sedation-sensitive patients, though the exact magnitude of that difference for any individual patient has not been verified against a specific comparative study in this review.

Neither label lists the other drug as an interaction. That silence reflects the absence of a shared primary metabolic pathway rather than proof that no interaction of any kind exists. Absence of a label warning is not the same as a study showing no effect.

The pharmacodynamic question: could the two drugs add to each other's blood pressure effect?

This is the mechanistically plausible part of the interaction, and it is where clinicians should focus.

Losartan lowers blood pressure partly by reducing angiotensin II-driven aldosterone release, which reduces sodium and water retention. Progesterone is structurally related to aldosterone and is understood pharmacologically to compete at the mineralocorticoid receptor, which can produce a mild natriuretic effect independent of the renin-angiotensin system. Because both drugs push in the same general direction on sodium handling, through different upstream mechanisms, an additive blood-pressure-lowering effect is biologically plausible.

What is not established here is the size of that effect in real patients taking losartan and micronized progesterone together. No dedicated randomized interaction trial of this specific pairing was located for this review. Extrapolating a specific number of millimeters of mercury from unrelated hormone-therapy or hypertension-trial data would overstate what is known, so this article does not provide one. Clinicians should treat the effect as real in principle and small to moderate in most patients, confirmed by measurement rather than assumed by mechanism.

The potassium question

Both drugs act, through different mechanisms, on the same downstream target: aldosterone-mediated potassium excretion in the kidney. Losartan reduces aldosterone activity as part of its intended effect, which can raise serum potassium, an effect well documented for ARBs generally in FDA labeling and reflected in the class's contraindication in severe hyperkalemia. Progesterone's mineralocorticoid-receptor competition could theoretically add a small further pressure in the same direction. This is a plausible, mechanism-based concern rather than a quantified, trial-confirmed one for this specific drug pair.

The practical implication does not depend on knowing the exact size of the effect. In patients who already carry hyperkalemia risk, meaning reduced kidney function, concurrent ACE inhibitor use, potassium-sparing diuretics, potassium supplements, or regular NSAID use, adding progesterone to losartan (or the reverse) is a reasonable trigger for a potassium check, not a reason to avoid the combination.

Sedation and fall risk

Oral micronized progesterone's sedative effect is well documented and is the basis for the bedtime-dosing instruction in its label. Losartan is not primarily sedating, but dizziness and, less commonly, orthostatic symptoms are recognized adverse effects of ARBs as a class. If both drugs are taken together, or if progesterone is taken during waking hours, a patient's dizziness or drowsiness could plausibly reflect an overlap of a hormone-driven CNS effect and an antihypertensive-driven blood pressure effect. Separating the dosing times (losartan in the morning, oral progesterone at bedtime, consistent with the progesterone label's own instruction) is a reasonable, low-cost precaution even though no trial specifically tested this timing strategy against the losartan-progesterone pairing.

Evidence-status interaction assessment

Monitoring approach

Before starting the second drug. Baseline seated and standing blood pressure, serum potassium, serum creatinine or eGFR, and a brief question about dizziness or sedation history, particularly in patients over 65 or with reduced kidney function.

Four to six weeks after starting or changing either drug. Repeat potassium and creatinine. Recheck blood pressure sitting and standing. Ask directly about dizziness on standing and daytime drowsiness, since patients often do not report these spontaneously or may attribute them to menopause itself.

Ongoing. Routine metabolic panel at intervals set by the prescriber based on kidney function and other risk factors. Any dose change to either drug, or a switch in progesterone route (oral to vaginal or the reverse), is a reasonable trigger to repeat the early monitoring steps rather than waiting for the next routine visit.

Populations that warrant closer attention

Reduced kidney function (roughly eGFR under 45). Both reduced clearance and the baseline hyperkalemia risk from CKD make potassium monitoring more important, and more frequent, when this combination is started or adjusted. Nephrology input is reasonable if potassium rises meaningfully above the normal range.

Concurrent ACE inhibitor, potassium-sparing diuretic, or regular NSAID use. Each of these independently raises hyperkalemia risk with an ARB. Adding progesterone on top does not have a separately quantified risk figure, but stacking multiple RAAS-active or renal-prostaglandin-blunting agents is a recognized general concern that argues for closer, not less, monitoring.

Age over 65. Reduced renal reserve and higher fall risk make the sedation and orthostatic considerations more consequential. Vaginal progesterone, which produces lower systemic hormone exposure than oral dosing, is a reasonable option to discuss in this group, though the decision should weigh endometrial protection needs and should be made with the prescribing clinician rather than self-directed.

Diabetic nephropathy or heart failure managed with losartan for organ protection, not just blood pressure. In these patients, losartan's benefit is not solely about blood pressure numbers. A drop in blood pressure after starting HRT is not, by itself, a reason to stop or sharply reduce losartan; the decision should weigh the reason losartan was prescribed in the first place, and should be made by the treating clinician.

When to seek prompt medical attention

A blood pressure reading consistently below 90/60 mmHg accompanied by dizziness or fainting, palpitations, unusual muscle weakness, or tingling in the extremities (possible signs of elevated potassium) should prompt a call to the prescriber or, if severe, urgent evaluation. These symptoms should not be assumed to be routine menopause or medication-adjustment effects without a blood pressure and potassium check.

What this article does not establish

No dedicated randomized or pharmacokinetic interaction study specifically pairing losartan and micronized progesterone was identified for this review. The mechanistic reasoning above (mineralocorticoid-receptor competition, aldosterone-related potassium handling, sedation from allopregnanolone) is drawn from each drug's independently documented pharmacology, not from a study that measured the two drugs together. Readers and clinicians who need a precise numeric estimate of blood pressure or potassium change from this specific combination should search current primary literature or a maintained clinical drug-interaction database directly, since this article intentionally does not manufacture a number that has not been demonstrated.

References

• U.S. Food and Drug Administration, Drugs@FDA database (search for current Cozaar and Prometrium prescribing information): https://www.accessdata.fda.gov/scripts/cder/daf/
• Centers for Disease Control and Prevention, NCHS data on hypertension prevalence: https://www.cdc.gov/nchs/products/databriefs/db364.htm